Abstract
B-type natriuretic peptide (BNP), initially identified in brain tissues, is now recognized as a key cardiac hormone. Numerous studies over the last decade have demonstrated that both exogenous and endogenous BNP prevent left ventricular (LV) hypertrophy in experimental settings, largely via activation of particulate guanylyl cyclase (pGC)-coupled receptors. BNP represents somewhat of a paradox, in that upregulation of BNP expression is widely used as a diagnostic marker for LV hypertrophy, diastolic dysfunction and heart failure in the clinic. We and others have postulated that BNP serves as an endogenous brake on the LV myocardium, seeking to curb the runaway train of signaling pathways that drive the progression from LV hypertrophy though remodeling, heart failure and death. This review summarizes the mechanisms of BNPs antihypertrophic actions, the role for cyclic GMP-mediated inhibition of pro-hypertrophic signaling, and BNPs impact on LV function. The improved understanding of the mechanisms of BNP regulation of LV hypertrophy and function that has emerged from both the experimental and clinical experience with this peptide provides new insight into the potential that BNP pharmacotherapy still offers for patients with LV hypertrophy.
Keywords: BNP, cardiomyocyte, cyclic GMP, hypertrophy, natriuretic peptides, nesiritide
Current Molecular Medicine
Title: B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
Volume: 9 Issue: 7
Author(s): Rebecca H. Ritchie, Anke C. Rosenkranz and David M. Kaye
Affiliation:
Keywords: BNP, cardiomyocyte, cyclic GMP, hypertrophy, natriuretic peptides, nesiritide
Abstract: B-type natriuretic peptide (BNP), initially identified in brain tissues, is now recognized as a key cardiac hormone. Numerous studies over the last decade have demonstrated that both exogenous and endogenous BNP prevent left ventricular (LV) hypertrophy in experimental settings, largely via activation of particulate guanylyl cyclase (pGC)-coupled receptors. BNP represents somewhat of a paradox, in that upregulation of BNP expression is widely used as a diagnostic marker for LV hypertrophy, diastolic dysfunction and heart failure in the clinic. We and others have postulated that BNP serves as an endogenous brake on the LV myocardium, seeking to curb the runaway train of signaling pathways that drive the progression from LV hypertrophy though remodeling, heart failure and death. This review summarizes the mechanisms of BNPs antihypertrophic actions, the role for cyclic GMP-mediated inhibition of pro-hypertrophic signaling, and BNPs impact on LV function. The improved understanding of the mechanisms of BNP regulation of LV hypertrophy and function that has emerged from both the experimental and clinical experience with this peptide provides new insight into the potential that BNP pharmacotherapy still offers for patients with LV hypertrophy.
Export Options
About this article
Cite this article as:
Ritchie H. Rebecca, Rosenkranz C. Anke and Kaye M. David, B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target, Current Molecular Medicine 2009; 9 (7) . https://dx.doi.org/10.2174/156652409789105499
DOI https://dx.doi.org/10.2174/156652409789105499 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on Biomarkers Recent Advances in Nanosystems and Strategies for Managing Leishmaniasis
Current Drug Targets Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Herbal Highs: Review on Psychoactive Effects and Neuropharmacology
Current Neuropharmacology Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Current Drug Metabolism Interaction studies of Withania somnifera’s key metabolite Withaferin A with different receptors associated with cardiovascular disease
Current Computer-Aided Drug Design Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Predictors of “Worsening Renal Function” in Patients Hospitalized in Internal Medicine Department
Current Drug Safety Therapeutic Potential of microRNA Against Th2-associated Immune Disorders
Current Topics in Medicinal Chemistry Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Sirtuin Family: A Link to Metabolic Signaling and Senescence
Current Medicinal Chemistry Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design Pharmacoproteomics in Cardiac Hypertrophy and Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets